



Title: Appointment of Nannette Rich to Head US Sales & Marketing

Date: 21st of December 2018

Program relevance: All Telix programs

Synopsis:

Telix is now a commercial stage and revenue-generating company, with several key North American relationships including Cardinal Health, Endocyte and Isologic. Telix's first US commercial activity is focused on the *illumet*TM prostate imaging kit for the preparation of ⁶⁸Ga-HBED-CC-PSMA (⁶⁸Ga-PSMA)¹. To lead this activity, Telix has appointed Nannette Rich as Vice President of Sales & Marketing, reporting to the President of Telix's US business, Dr. Bernard Lambert. Nannette is an ex-Mallinckrodt (now Curium) executive with a track record of product launch in the nuclear medicine field and relevant experience with ⁶⁸Ga (gallium)-based products.

Key points for investors:

- This is Telix's first dedicated commercial hire and reflects the Company's commercial focus on the US market
- Nannette Rich is an experienced sales & marketing executive that brings prior experience of nuclear medicine product launch in the United States

¹ Sold as an investigational product. This product does not currently have regulatory approval in the United States or Canada.



Appointment of Nannette Rich to Lead US Sales & Marketing

Melbourne (Australia) and Indianapolis (USA) – 21 December 2019. Telix Pharmaceuticals Limited (ASX:TLX) ("Telix", the "Company"), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has today announced the appointment of Nannette Rich as Vice President of Sales and Marketing of Telix Pharmaceuticals (US), Inc. ("Telix US"). Nannette will have commercial responsibility in North America for the Telix product portfolio, with initial focus on the Company's *illumet*TM prostate cancer imaging program.

Telix US President Dr. Bernard Lambert stated, "Nannette has been working with Telix US as a consultant through the soft launch of the *illumet*TM prostate imaging product and we are pleased that she will be formally joining the team in an executive capacity. Nannette's extensive experience in business development and track record in launching nuclear medicine products will be invaluable in supporting the introduction of Telix's product portfolio to the US market."

Nannette has a Bachelor of Science degree in chemistry from the University of Missouri and initially worked as a research chemist at PPG Industries. In the '90s Nannette commenced a commercial career at Burroughs Wellcome (now GSK) followed by a series of sales and commercial positions at Cytoc Corporation (now Hologic), Covidien, Tyco Healthcare/Mallinckrodt and KV Pharmaceuticals. At Mallinckrodt, Nannette was Director of Nuclear Cardiology Marketing, responsible for the launch of the sestimibi product and managed a USD \$165M drug franchise. At Mallinckrodt (now Curium) she also led the business case for the production of ⁶⁸Ge (germanium) used in ⁶⁸Ga (gallium) generators and has extensive commercial experience with ⁶⁸Ga-based products.

Nannette Rich stated, "I am pleased to be joining Telix and to be part of a company that is fundamentally disrupting the field of nuclear medicine. Over the past twelve months, Telix has demonstrated their commitment and ability to rapidly commercialize radiopharmaceutical products, with a global reach. I look forward to contributing to this dynamic business."

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations (Australia)

Arthur Chan
WE Buchan
Tel: +61 2 9237 2805
Email: arthurc@we-buchan.com

Telix Investor Relations (US)

Lisa Wilson
In-Site Communications
Tel: +1 212 452 2793
Email: lwilson@insitecony.com



Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorization in any jurisdiction.